Cogent Biosciences, Inc. (COGT) NASDAQ

Currency In USD

Cogent Biosciences, Inc.

Address

200 Cambridge Park Drive

Waltham, MA 02140

United States of America (the)

Phone

617 945 5576

Website

https://www.cogentbio.com

Sector

Healthcare

Industry

Biotechnology

Employees

205

First IPO Date

March 29, 2018

Key Executives

Name	Title	Pay	Year Born
Andrew R. Robbins	President, Chief Executive Officer & Director	1.32M	1976
Cole Pinnow	Chief Commercial Officer	754,602	1975
John L. Green	Chief Financial Officer & Principal Accounting Officer	834,275	1980
John Edward Robinson	Chief Scientific Officer	868,743	1974
Jessica Sachs	Chief Medical Officer	896,623	1975
Rachael Easton	Senior Vice President of Clinical Development	0	N/A
Abb Hayden	Senior Vice President of Sales	0	N/A
Brad Barnett	Chief Technology Officer	0	N/A
Dana R. Martin	Senior Vice President of Medical Affairs & Chief Patient Officer	0	N/A
Evan D. Kearns	Chief Legal Officer & Corporate Secretary	0	1980
Christi Waarich	Senior Director of Investor Relations	0	N/A
Erin Schellhammer	Chief People Officer	0	N/A
Brad Fell	Senior Vice President of Chemistry	0	N/A

Description

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.